Placental kappa binding site : interaction with dynorphin and its possible implication in hCG secretion.
We have previously demonstrated that human placenta contains a homogenous population of kappa binding sites. The selective interaction of dynorphin with these opiate binding sites suggests a possible physiological implication of this endogenous opioid system in the placenta physiology. Ethylketocyclazocine stimulate K+-induced hCG release. This fact favours the hypothesis of a participation of placental opiate receptor on hCG secretion.
D000701:Analgesics, Opioid / Q000494:pharmacology; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D003496:Cyclazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D004399:Dynorphins; D004723:Endorphins / Q000494:pharmacology*; D016314:Ethylketocyclazocine; D005260:Female; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology*; D010920:Placenta / Q000187:drug effects / Q000378:metabolism*; D011247:Pregnancy; D011957:Receptors, Opioid / Q000187:drug effects / Q000378:metabolism*; D017473:Receptors, Opioid, kappa
D000701:Analgesics, Opioid; D006063:Chorionic Gonadotropin; D004723:Endorphins; D010446:Peptide Fragments; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D016314:Ethylketocyclazocine; C026843:dynorphin (1-13); D004399:Dynorphins; D003496:Cyclazocine